Home / Healthcare/ Long-acting injection a shot in the arm for GSK’s HIV business

Long-acting injection a shot in the arm for GSK’s HIV business


Comments / {{hitsCtrl.values.hits}} Views / Thursday, 16 August 2018 00:00

Facebook

Reuters: A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business.

GSK’s majority-owned ViiV Healthcare unit said yesterday that the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen after 48 weeks of a clinical trial.

The result from the big Phase III study is a boost for GSK’s goal of developing dual therapies that are easier to tolerate than conventional triple ones, and shares in GSK rose 1.5%. It follows recent positive data from combining two oral drugs.

GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the US drugmaker that dominates the $ 26 billion-a-year HIV market.

Shares in Gilead, which also announced late on Tuesday that its Chief Medical Officer Andrew Cheng was leaving the company, fell 3%.

Gilead currently has a market share of around 52% against GSK’s 22%, but Deborah Waterhouse, who heads the British drugmaker’s HIV unit, says she hopes to overtake her US rival by the mid-2020s.

That is a bold ambition, since many analysts have been expecting GSK to lose market share to Gilead’s new triple drug Biktarvy, rather than see it gain ground.



Slow burn

Liberum analyst Roger Franklin, who rates GSK a ‘buy’, believes the company’s dual-drug strategy has been under-appreciated by the market.

“Whilst duals will likely be a slow burn as resistance data is collected and the regimen gains credence among physicians, the prospects are much improved now versus a year ago,” he said.

GSK is betting that a shift to using two drugs rather than three will boost its sales by offering patients a therapy with greater convenience and fewer toxic side effects. In certain cases, depending on the drugs used, two-drug regimens will also be significantly cheaper.

Still, some doctors worry that using just two drugs to keep the AIDS virus at bay might risk drug resistance because HIV will only have to evade two drugs rather than three. That is certainly the view at Gilead, which is sticking with three.

In the case of the cabotegravir and rilpivirine monthly injection, GSK said drug resistance results in the latest study were consistent with data from earlier smaller trials. It did not go into further details but said full results would be presented at an upcoming scientific meeting.

ViiV Chief Scientific and Medical Officer John Pottage argued the novel injection offered an alternative long-term treatment for patients.

“If approved, this regimen would give people living with HIV one month between each dose of antiretroviral therapy, changing HIV treatment from 365 dosing days per year, to just 12,” he said.

Results from a second trial of cabotegravir and rilpivirine are expected later this year. Rilpivirine was developed by Johnson and Johnson and GSK is working with the US drugmaker on the new injection regimen.


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

No more stones to break Sri Lankan bones

Friday, 19 April 2019

Trial by fire is not a new ordeal to Christian community. It predates Notre Dame and Nazism by millennia. In fact, a decade or so before Nero torched believers to light Roman avenues, Jewish religious leaders put Jesus-followers to the test as the Ch


Wounding the social psyche

Friday, 19 April 2019

In this article, I intend to discuss the serious wounds inflicted on the psyche of Sri Lankan society, which have not received adequate attention, but need immediate cure, for they might develop into a dangerous cancer if not treated without further


What 5G could be to Game of Thrones (and vice versa)

Friday, 19 April 2019

We will be hearing a lot about these two seemingly unrelated topics this month. In a hurriedly but meticulously organised event, Dialog Axiata recently demonstrated 5G applications for the first time in South Asia. 5G will be commercially available


On time – Only for a week! A must-change!

Thursday, 18 April 2019

We are in April and the month where we witness the declaration of a new year as per our traditional practice. It is that period of time when a huge majority of our population, which certainly can be counted in millions, intends to act in unison and q


Columnists More